Skip to main content
Erschienen in: International Urology and Nephrology 4/2009

01.12.2009 | Urology - Editorial

Editorial comment

verfasst von: Michele Pavone-Macaluso

Erschienen in: International Urology and Nephrology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Excerpt

In an interesting paper by Nishimura et al. [1], the authors, from the Saga University of Japan, address an important topic—that of obtaining a reliable staging of deeply infiltrating bladder cancer after a neoadjuvant treatment, namely either chemotherapy or chemoradiation, using modern imaging techniques such as magnetic resonance imaging (MRI). …
Literatur
1.
Zurück zum Zitat Nishimura K, Fujiyama C, Nakashima K, Satoh Y, Tokuda Y, Uozumi J (2009) The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol. doi:10.1007/s11255-009-9566-5 Nishimura K, Fujiyama C, Nakashima K, Satoh Y, Tokuda Y, Uozumi J (2009) The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol. doi:10.​1007/​s11255-009-9566-5
2.
Zurück zum Zitat Solsona E, Climent MA, Iborra I, Collado A, Rubio A et al (2009) Bladder preservation in selected patients with muscle-invasive cancer by complete transurethral resection of the bladder plus systemic chmotherapy: long-term follow-up of a phase 2 non randomized comparative trial with radical cystectomy. Eur Urol 55:911–921CrossRefPubMed Solsona E, Climent MA, Iborra I, Collado A, Rubio A et al (2009) Bladder preservation in selected patients with muscle-invasive cancer by complete transurethral resection of the bladder plus systemic chmotherapy: long-term follow-up of a phase 2 non randomized comparative trial with radical cystectomy. Eur Urol 55:911–921CrossRefPubMed
3.
Zurück zum Zitat Montie JE, Pavone-Macaluso M, Tazaki H, Albrecht W, Bono A et al (1995) What are the risks of cystectomy and the advances in perioperative care? Int J Urol 2(Suppl 2):89–104PubMed Montie JE, Pavone-Macaluso M, Tazaki H, Albrecht W, Bono A et al (1995) What are the risks of cystectomy and the advances in perioperative care? Int J Urol 2(Suppl 2):89–104PubMed
4.
Zurück zum Zitat Prasad SM, Ferreria M, Berry AM, Lipsitz SR, Richie JP et al (2009) Surgical Apgar outcome score: perioperative risk assessment for radical cystectomy. J Urol 181:1046–1052CrossRefPubMed Prasad SM, Ferreria M, Berry AM, Lipsitz SR, Richie JP et al (2009) Surgical Apgar outcome score: perioperative risk assessment for radical cystectomy. J Urol 181:1046–1052CrossRefPubMed
5.
Zurück zum Zitat Shabsigh A, Korets R, Vora KC, Brooks CM, Gromin AM et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55:164–176CrossRef Shabsigh A, Korets R, Vora KC, Brooks CM, Gromin AM et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55:164–176CrossRef
6.
Zurück zum Zitat Splinter TAW, Pavone-Macaluso M, Jacqmin D, Roberts JT, Carpentier P et al (1992) A European organization for research and treatment of cancer genitourinary group. Phase II study of chemotherapy in stage T3–T4 No–x Mo transitional cell carcinoma of the bladder: evaluation of clinical response. J Urol 148:1793–1796PubMed Splinter TAW, Pavone-Macaluso M, Jacqmin D, Roberts JT, Carpentier P et al (1992) A European organization for research and treatment of cancer genitourinary group. Phase II study of chemotherapy in stage T3–T4 No–x Mo transitional cell carcinoma of the bladder: evaluation of clinical response. J Urol 148:1793–1796PubMed
7.
Zurück zum Zitat Pavone-Macaluso M, Serretta V, Ingargiola GB, Corselli G, Piazza F et al (1994) Neoadjuvant chemotherapy of invasive bladder cancer with cisplatin and methotrexate in 71 patients. Prognostic value of clinical response. In: Giuliani L, Santi L, Boccardo F, Pescatore D (eds) New trends in diagnosis and treatment of bladder cancer. Oncology, Sympomed, München, vol 3, pp 399–405 Pavone-Macaluso M, Serretta V, Ingargiola GB, Corselli G, Piazza F et al (1994) Neoadjuvant chemotherapy of invasive bladder cancer with cisplatin and methotrexate in 71 patients. Prognostic value of clinical response. In: Giuliani L, Santi L, Boccardo F, Pescatore D (eds) New trends in diagnosis and treatment of bladder cancer. Oncology, Sympomed, München, vol 3, pp 399–405
8.
Zurück zum Zitat Pavone-Macaluso M, Serretta V, Corselli G, Jacqmin D, Sylvester R et al (1992) EORTC studies of first-line chemotherapy in invasive bladder cancer. In: Villavicencio H, Fair WR (eds) Societé Internationale d’Urologie Reports: Evaluation of chemotherapy in bladder cancer. Churchill Livingstone, Edinburgh, pp 161–170 Pavone-Macaluso M, Serretta V, Corselli G, Jacqmin D, Sylvester R et al (1992) EORTC studies of first-line chemotherapy in invasive bladder cancer. In: Villavicencio H, Fair WR (eds) Societé Internationale d’Urologie Reports: Evaluation of chemotherapy in bladder cancer. Churchill Livingstone, Edinburgh, pp 161–170
9.
Zurück zum Zitat International collaboration of trialists (2000) Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 355:1491–1498CrossRef International collaboration of trialists (2000) Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 355:1491–1498CrossRef
10.
Zurück zum Zitat Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866CrossRefPubMed Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866CrossRefPubMed
11.
Zurück zum Zitat Pavone-Macaluso M, Hall RR, Hirao Y et al (1998) The role of neoadjuvant chemotherapy for invasive bladder cancer. Is there a benefit for survival or preserving the bladder? Urol Oncol 4:154–167CrossRef Pavone-Macaluso M, Hall RR, Hirao Y et al (1998) The role of neoadjuvant chemotherapy for invasive bladder cancer. Is there a benefit for survival or preserving the bladder? Urol Oncol 4:154–167CrossRef
12.
Zurück zum Zitat Sternberg CN, Pansadoro V, Calabrò F et al (2003) Can patients selection for bladder preservation be based on response to chemotherapy? Cancer 97:1644–1652CrossRefPubMed Sternberg CN, Pansadoro V, Calabrò F et al (2003) Can patients selection for bladder preservation be based on response to chemotherapy? Cancer 97:1644–1652CrossRefPubMed
13.
Zurück zum Zitat Calabrò F, Sternberg CN (2009) Neo-adjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 55:348–358CrossRefPubMed Calabrò F, Sternberg CN (2009) Neo-adjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 55:348–358CrossRefPubMed
14.
Zurück zum Zitat Azuma H, Kotake Y, Yamamoto K, Sakamoto T, Kiyama S et al (2008) Effect of combined therapy using balloon-occluded arterial infusion of cisplatin with hemodialysis with concurrent radiation for locally invasive bladder cancer. Am J Clin Oncol 31:11–21CrossRefPubMed Azuma H, Kotake Y, Yamamoto K, Sakamoto T, Kiyama S et al (2008) Effect of combined therapy using balloon-occluded arterial infusion of cisplatin with hemodialysis with concurrent radiation for locally invasive bladder cancer. Am J Clin Oncol 31:11–21CrossRefPubMed
15.
Zurück zum Zitat Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF et al (2009) Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73:147–152CrossRefPubMed Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF et al (2009) Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73:147–152CrossRefPubMed
Metadaten
Titel
Editorial comment
verfasst von
Michele Pavone-Macaluso
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2009
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9582-5

Weitere Artikel der Ausgabe 4/2009

International Urology and Nephrology 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

22.05.2024 Obstipation Nachrichten

Bei chronischer Verstopfung wirken Kiwis offenbar besser als Flohsamenschalen. Das zeigen die Daten aus einer randomisierten Studie, die der Gastroenterologe Oliver Pech beim Praxis-Update vorstellte.

So häufig greift rheumatoide Arthritis auf Organe über

21.05.2024 Rheumatoide Arthritis Nachrichten

Im Verlauf von rheumatoider Arthritis entwickeln viele Patienten extraartikuläre Manifestationen. Schwedische Forscher haben sich mit der Inzidenz und den Risikofaktoren befasst.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.